<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908347</url>
  </required_header>
  <id_info>
    <org_study_id>MP1032-CT02</org_study_id>
    <nct_id>NCT02908347</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients</brief_title>
  <official_title>A Randomized (1:1), Double-blind, Parallel, Placebo-controlled Exploratory Pilot Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Systemic (po) Application of MP1032 in Patients With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetrioPharm AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MetrioPharm AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of
      oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks. Secondary
      endpoints to evaluate clinical parameters for psoriasis during the 6 week treatment period
      and a 4-week follow up will provide an opportunity to perform a first assessment of oral
      MP1032's clinical efficacy in the treatment of moderate to severe psoriasis.

      The study population will consist of 44 enrolled (40 completed) patients with moderate to
      severe chronic plaque psoriasis. Patients must be able to provide written consent and meet
      all the inclusion criteria and none of the exclusion criteria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, parallel, placebo-controlled exploratory pilot
      study to evaluate safety, pharmacokinetics and efficacy of systemic oral (po) administration
      of 100 mg MP1032 bid in adult patients with moderate to severe chronic plaque psoriasis.

      The study design consists of a 28-day screening/run-in period, a 42-day treatment period, 1
      day for the End of Treatment visit, and a 28-day follow-up period. Forty-four patients who
      meet the entry criteria will be randomized on Day 1 in a 1:1 ratio to receive either 100 mg
      MP1032 or placebo orally twice daily for 42 days. The goal is to have 40 patients (20 in each
      treatment group) complete the study.

      Pharmacokinetic sampling will occur on 3 designated study days. Safety will be monitored from
      the signing of the informed consent form (ICF) until the last follow-up visit on Day 71.

      Efficacy will be assessed on 6 designated study days using the following assessments: PASI,
      PGA, DLQI, mNAPSI, and EQ-5D 5L (VAS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs</measure>
    <time_frame>Continuously from Treatment Start until the last follow-up visit on Study Day 71</time_frame>
    <description>Number of TEAEs (Treatment Emergent Adverse Events) occured was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Related TEAEs by SOC</measure>
    <time_frame>Continuously from Treatment Start until the last follow-up visit on Study Day 71</time_frame>
    <description>Number of related TEAEs (Treatment Emergent Adverse Events) occured by SOC (System Organ class) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Patients With TEAEs</measure>
    <time_frame>Continuously from Treatment Start until the last follow-up visit on Study Day 71</time_frame>
    <description>Number of patients with TEAEs (Treatment Emergent Adverse Events) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Patients With Related TEAEs by SOC</measure>
    <time_frame>Continuously from Treatment Start until the last follow-up visit on Study Day 71</time_frame>
    <description>Number of patients with related TEAEs (Treatment Emergent Adverse Events) occured by SOC (System Organ class) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - Plasma Concentrations</measure>
    <time_frame>Study Days 1, 15, 29 and 43</time_frame>
    <description>Study Day 1 - sampling 15 minutes, 30 minutes, 1 hour and 2 hours postdose Study Days 15, 29 and 43 - only one sample was taken any time postdose (time of the last dose was recorded).
No statistical Evaluation has been performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Maximum observed plasma concentration (Cmax)as observed on Day 1 with sampling times of 15 minutes, 30 minutes, 1 hour, and 2 hours postdose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - Time</measure>
    <time_frame>Study Day 1</time_frame>
    <description>Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
t max = Time corresponding to occurence of Cmax t last = Time of last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - Area Under the Curve (AUC)</measure>
    <time_frame>Study Day 1</time_frame>
    <description>AUC (lin-log) - Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
AUC 2h = area under the plasma concentration-time curve from time zero to 2 hours AUC t = area under the plasma concentration-time curve from time zero to the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) - Area Under the Curve (AUC) - Subgroups</measure>
    <time_frame>Study Day 1</time_frame>
    <description>AUC (lin-log) - Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
AUC 2h = area under the plasma concentration-time curve from time zero to 2 hours AUC t = area under the plasma concentration-time curve from time zero to the last quantifiable concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area Severity Index (PASI) - Observed PASI Values</measure>
    <time_frame>Study Day 1, 43, 57 and 71</time_frame>
    <description>Observed PASI values. PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD, ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area Severity Index (PASI) - Change From Baseline</measure>
    <time_frame>Study Day 1 and 43</time_frame>
    <description>Change from Baseline (PASI value Day 43 - PASI value at Day 1) / Treatment difference on Day 43
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
Variables will be summarized by descriptive statistics (n, mean, SD), difference between groups is analyzed via non-parametric statistical testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area Severity Index (PASI) - PASI Percentage Change - Including Subgroup Analysis AUC2h</measure>
    <time_frame>Study Day 1, 29 and 43</time_frame>
    <description>The PASI percentage change in % at Day 29 is calculated as PASI of (Day 29 - Baseline)/Baseline*100).
The PASI percentage change in % at Day 43 is calculated as PASI of (Day 43 - Baseline)/Baseline*100).
Baseline = Study Day 1
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area Severity Index (PASI) - PASI Percentage Change - Including Subgroup Analysis AUCt</measure>
    <time_frame>Study Day 1, 29 and 43</time_frame>
    <description>The PASI percentage change in % at Day 29 is calculated as PASI of (Day 29 - Baseline)/Baseline*100).
The PASI percentage change in % at Day 43 is calculated as PASI of (Day 43 - Baseline)/Baseline*100).
Baseline = Study Day 1
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area Severity Index (PASI) - PASI 30 and PASI 50 - Number of Patients</measure>
    <time_frame>Study Day 1, 29 and 43</time_frame>
    <description>PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
PASI 30 and PASI 50 are related to the number of patients who had at least 30% (PASI 30) or 50% (PASI 50) reduction in PASI score compared to baseline (Study Day 1).
Variables are summarized by descriptive statistics (n, mean, SD, ). Difference between groups has been analyzed via Fisher exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area Severity Index (PASI) - PASI 30 and PASI 50 - Responder Frequency</measure>
    <time_frame>Study Day 1, 29 and 43</time_frame>
    <description>PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
PASI 30 and PASI 50 are related to the number of patients (responder frequency (%)) who had at least 30% (PASI 30) or 50% (PASI 50) reduction in PASI score compared to baseline (Study Day 1).
Variables are summarized by descriptive statistics (n, mean, SD, ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment (PGA) - Observed Values and Change From Baseline</measure>
    <time_frame>Study Day 1 and 43</time_frame>
    <description>PGA is the physician's global assessment of the severity of psoriasis using a 7-point scale from 0 (clear) to 6 (severe).
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at Study Day 43 (End of Treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI) - Observed Values and Change From Baseline.</measure>
    <time_frame>Study Day 1 and 43</time_frame>
    <description>DLQI is a total score ranging from 0 (life quality is not affected) to 30 (deep impact on life quality) computed from answers to 10 questions, with each answer scored from 0 (not at all) to 3 (very much).
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) on end of treatment (Day 43).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D 5L Visual Analogue Scale (VAS)</measure>
    <time_frame>Study Day 1 and 43</time_frame>
    <description>EQ-5D (VAS) is a total score which records the patients' self-rated health status with the scale numbered 0 (worst imaginable) to 100 (best imaginable)
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at end of Treatment (Study Day 43).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Nail Psoriasis Severity Index (mNAPSI) - Observed Values and Change From Baseline</measure>
    <time_frame>Study Day 1 and 43</time_frame>
    <description>mNAPSI score is a total score computed from answers to 7 questions, 3 of which can be answered with a score ranging from 0 to 3, and 4 of which can be answered with a score ranging from 0 to 1. The total score ranges from 0 to 13, the higher the score the worse the outcome.
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at end of Treatment (Study Day 43).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Psoriasis</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>MP1032</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo to MP1032:
2 capsules of Placebo are provided orally twice daily for 42 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP1032</intervention_name>
    <description>hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
    <arm_group_label>MP1032</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>hard gelatine capsules without active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants legally competent to sign and give informed consent.

          2. Adult male and female patients aged 18 to 65 years with chronic plaque psoriasis:

               1. PASI score &gt; 10 at screening and

               2. Disease duration of ≥ 6 months at the initiation of study medication.

          3. Body Mass Index (BMI) between 18.5 and 34.9 kg/m2.

          4. Diagnosis of chronic plaque psoriasis confirmed by a dermatologist/physician.

          5. Women of childbearing potential (WCBP) must have a negative urine pregnancy test at
             Screening (Visit 1). In addition, sexually active WCBP must agree to use 2 forms of
             adequate contraception throughout the trial.

          6. Post-menopausal women with spontaneous amenorrhea for at least 12 months and serum
             levels follicle stimulating hormone (FSH) Levels indicating post-menopausal state as
             per local laboratory reference ranges. Females on hormone replacement therapy (HRT)
             and whose menopausal status is in doubt must discontinue HRT to allow confirmation of
             post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 to
             4 weeks will elapse between the cessation of therapy and the blood draw; this interval
             depends on the type and dosage of HRT. Following confirmation of their post-menopausal
             status, they can resume use of HRT during the study. Sterilized women may be included.

          7. Patients must meet the following clinical laboratory criteria:

               1. White blood cell count ≥ 3.5 x 10^9/L

               2. Platelet count ≥ 100 x 10^9/L

               3. Serum creatinine ≤ 1.5 x upper limit of normal (ULN); estimated glomerular
                  filtration rate &gt; 60 mL/min

               4. Total bilirubin ≤ 1.5 x ULN

               5. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 1.5 x ULN

               6. Hemoglobin ≥ lower limit of normal as per local laboratory reference ranges for
                  women and men accordingly

               7. No coagulopathy (International Normalized Ratio [INR] &lt; 1.5).

          8. Patients agree not to increase normal sun exposure during the course of the study.

          9. Patients are able to swallow 2 small capsules during each administration.

         10. Patients are considered reliable and capable of adhering to the protocol (eg, able to
             understand and complete diaries), visit schedule, or medication intake according to
             the judgment of the Investigator.

        Exclusion Criteria:

          1. Patients with non-plaque form of psoriasis (erythrodermic, guttate, pustular or palmo
             plantar psoriasis; severe form of psoriasis arthritis, inverse form of psoriasis).
             Mild to moderate cases of psoriasis arthritis are allowed provided there is no impact
             on study objectives as determined by the Investigator.

          2. Patients with drug-induced psoriasis.

          3. Evidence of skin conditions at the time of screening visit other than psoriasis that
             would interfere with evaluations of the effect of study medication on psoriasis.

          4. Patients with any serious medical condition, laboratory abnormality, or psychiatric
             illness that would prevent the patient from signing the informed consent form.

          5. Pregnant or lactating females or females planning to become pregnant during the study
             and/or within 28 days following the last dose of study medication.

          6. Male patients planning a partner pregnancy or sperm donation during the study or
             within 3 months following the last dose of study medication.

          7. Known allergies to mannitol, macrophage modulators, and gelatin.

          8. Patients with a recent history or current signs or symptoms, as determined by the
             Investigator, of severe, progressive viral or bacterial infections, of clinically
             significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic,
             renal, hematologic, immunologic insufficiency disease (excluding psoriasis) requiring
             systemic treatment or other major diseases, which are not well controlled and may
             interfere with the conduct of the trial.

          9. Patients with active malignancy or history of malignancy, except for basal cell or
             squamous cell carcinoma and actinic keratosis. Basal cell carcinoma and small squamous
             cell carcinoma of the skin which have been excised according to guidelines within the
             last 5 years or in situ cervical carcinoma that has been fully treated and shows no
             evidence of recurrence are allowed.

         10. Clinically significant abnormality on 12-lead electrocardiogram (ECG) at screening.

         11. Positive human immunodeficiency virus (HIV), hepatitis B or hepatitis C laboratory
             result.

         12. Previous strong sun exposure (eg, sea holiday) within the 28 days before study
             medication initiation.

         13. Known photo allergy and/or experienced drug-induced photo toxicity.

         14. Elective (planned) hospitalization or medical intervention preventing patient from
             following the protocol requirements.

         15. Prior Treatment: Drug class &gt;&gt; Last dose prior to study medication initiation (washout
             period)

             Topical psoriasis medications (including, but not limited to corticosteroids,
             calcipotriene, topical vitamin D derivates, retinoids, coal tar) &gt;&gt; 14 days

             Topical immunosuppressive drugs (tacrolimus, pimecrolimus, or anthralin) &gt;&gt; 14 days
             (Exception: Non-medicated emollients, moisturizers and sunscreens will be allowed),
             Use of low potency topical steroids for critical areas such as the face, genitalia,
             and scalp may be allowed until 24 hours prior to randomization.

             Systemic treatment (non-biologic): Systemic immunosuppressant agents (eg:
             methotrexate, cyclosporine, azathioprine), Systemic fumarate, Systemic corticosteroids
             &gt;&gt; 28 days

             Phototherapy or photochemotherapy/photosensitizing drugs &gt;&gt; 28 days

             Systemic retinoids &gt;&gt; 12 weeks

             Any investigational drug &gt;&gt; 24 weeks (systemic); 4 weeks (topical)

             Any Anti-TNFs: Infliximab, adalimumab, golimumab, etanercept, etc. &gt;&gt; 12 weeks

             Other Biologics and other systemic therapies: ustekinumab, alefacept, apremilast,
             Efalizumab, certolizumab pegol, secukinumab, etc. &gt;&gt; 24 weeks

             Rituximab &gt;&gt; 12 months

         16. Drinking or ingesting grapefruit, pomegranate, grapefruit juice or grapefruit
             containing products within 14 days of study medication initiation.

         17. Planned use of any ultraviolet (UV) phototherapy or photochemotherapy/photosensitizing
             drugs during the course of the study and within 28 days following the last dose of the
             study medication.

         18. Patients with a history of chronic alcohol or drug abuse within 6 months of study
             medication initiation.

         19. Patients employed by MetrioPharm or a contract research organization (CRO) involved in
             the clinical study.

         20. Vulnerable patients (eg, patients kept in detention).

         21. Patients who are unable to communicate, read and understand the local language, or who
             display any other condition, which, in the Investigator's opinion, makes them
             unsuitable for clinical study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anke Gauliard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rothaar Studien GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10783</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAREXEL International GmbH, Klinikum Westend</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Dresden GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Prof. Dr. Vanscheidt und Dr. Ukat</name>
      <address>
        <city>Freiburg</city>
        <zip>79100</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <results_first_submitted>August 1, 2018</results_first_submitted>
  <results_first_submitted_qc>January 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2019</results_first_posted>
  <last_update_submitted>January 21, 2019</last_update_submitted>
  <last_update_submitted_qc>January 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plaque psoriasis</keyword>
  <keyword>chronic</keyword>
  <keyword>moderate</keyword>
  <keyword>severe</keyword>
  <keyword>Plaque</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MP1032</title>
          <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MP1032</title>
          <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs</title>
        <description>Number of TEAEs (Treatment Emergent Adverse Events) occured was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
        <time_frame>Continuously from Treatment Start until the last follow-up visit on Study Day 71</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of TEAEs</title>
          <description>Number of TEAEs (Treatment Emergent Adverse Events) occured was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
          <units>TEAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Related TEAEs by SOC</title>
        <description>Number of related TEAEs (Treatment Emergent Adverse Events) occured by SOC (System Organ class) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
        <time_frame>Continuously from Treatment Start until the last follow-up visit on Study Day 71</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Related TEAEs by SOC</title>
          <description>Number of related TEAEs (Treatment Emergent Adverse Events) occured by SOC (System Organ class) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
          <units>TEAEs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders - Administration Site Conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Patients With TEAEs</title>
        <description>Number of patients with TEAEs (Treatment Emergent Adverse Events) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
        <time_frame>Continuously from Treatment Start until the last follow-up visit on Study Day 71</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Patients With TEAEs</title>
          <description>Number of patients with TEAEs (Treatment Emergent Adverse Events) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Patients With Related TEAEs by SOC</title>
        <description>Number of patients with related TEAEs (Treatment Emergent Adverse Events) occured by SOC (System Organ class) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
        <time_frame>Continuously from Treatment Start until the last follow-up visit on Study Day 71</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Treatment Emergent Adverse Events (TEAEs) - Number of Patients With Related TEAEs by SOC</title>
          <description>Number of patients with related TEAEs (Treatment Emergent Adverse Events) occured by SOC (System Organ class) was determined by treatment group.
Furthermore, the absolute and relative frequencies for patients with a given AE, as well as the number of events of the individual AEs that have occurred throughout the study (inclusive screening), were determined within each treatment group and system organ class. Results thereto are provided in the section &quot;Reported Adverse Events&quot;.
AEs are collected throughout the study. Abnormal values received from Clinical Laboratory Safety Testing (hematology, biochemistry and urinalysis on Study Days 1, 15, 29, 43, 57 and 71), Vital Signs (Systolic blood pressure, diastolic blood pressure, heart rate, tympanic body temperature and respiration rate on Study Days 1, 15, 29, 43, 57 and 71), ECG (Study Days 1, 43 and 71) and Physical Examination (Study Days 1, 43 and 71) were also handled as AE.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders - Administration Site Conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin and Subcutaneous Tissue Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK) - Plasma Concentrations</title>
        <description>Study Day 1 - sampling 15 minutes, 30 minutes, 1 hour and 2 hours postdose Study Days 15, 29 and 43 - only one sample was taken any time postdose (time of the last dose was recorded).
No statistical Evaluation has been performed.</description>
        <time_frame>Study Days 1, 15, 29 and 43</time_frame>
        <population>Participants who gave plasma for PK data and finished the study. (Data from study day 43 were not calculated since less than one-third of the individual data points were quantifiable at the nominal time point.)</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) - Plasma Concentrations</title>
          <description>Study Day 1 - sampling 15 minutes, 30 minutes, 1 hour and 2 hours postdose Study Days 15, 29 and 43 - only one sample was taken any time postdose (time of the last dose was recorded).
No statistical Evaluation has been performed.</description>
          <population>Participants who gave plasma for PK data and finished the study. (Data from study day 43 were not calculated since less than one-third of the individual data points were quantifiable at the nominal time point.)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 - 15 minutes postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.3" spread="153.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 30 minutes postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.861" spread="64.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.875" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.677" spread="6.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.545" spread="151.406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.652" spread="149.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK) - Maximum Observed Concentration (Cmax)</title>
        <description>Maximum observed plasma concentration (Cmax)as observed on Day 1 with sampling times of 15 minutes, 30 minutes, 1 hour, and 2 hours postdose</description>
        <time_frame>Study Day 1</time_frame>
        <population>PK analysis set - Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) - Maximum Observed Concentration (Cmax)</title>
          <description>Maximum observed plasma concentration (Cmax)as observed on Day 1 with sampling times of 15 minutes, 30 minutes, 1 hour, and 2 hours postdose</description>
          <population>PK analysis set - Per Protocol Set</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.585" spread="124.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK) - Time</title>
        <description>Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
t max = Time corresponding to occurence of Cmax t last = Time of last quantifiable concentration</description>
        <time_frame>Study Day 1</time_frame>
        <population>PK analysis set - Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) - Time</title>
          <description>Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
t max = Time corresponding to occurence of Cmax t last = Time of last quantifiable concentration</description>
          <population>PK analysis set - Per Protocol Set</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="0.25" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t last</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="1" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area Severity Index (PASI) - Observed PASI Values</title>
        <description>Observed PASI values. PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD, ).</description>
        <time_frame>Study Day 1, 43, 57 and 71</time_frame>
        <population>Number of patients may vary between days due to drop outs or missing data points</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area Severity Index (PASI) - Observed PASI Values</title>
          <description>Observed PASI values. PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD, ).</description>
          <population>Number of patients may vary between days due to drop outs or missing data points</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Treatment Start)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.03" spread="7.203"/>
                    <measurement group_id="O2" value="17.25" spread="7.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (End of Treatment)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.03" spread="9.509"/>
                    <measurement group_id="O2" value="14.69" spread="8.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (Follow Up 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.28" spread="10.681"/>
                    <measurement group_id="O2" value="15.97" spread="8.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71 (Follow Up 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.21" spread="10.03"/>
                    <measurement group_id="O2" value="16.09" spread="9.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area Severity Index (PASI) - Change From Baseline</title>
        <description>Change from Baseline (PASI value Day 43 - PASI value at Day 1) / Treatment difference on Day 43
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
Variables will be summarized by descriptive statistics (n, mean, SD), difference between groups is analyzed via non-parametric statistical testing.</description>
        <time_frame>Study Day 1 and 43</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area Severity Index (PASI) - Change From Baseline</title>
          <description>Change from Baseline (PASI value Day 43 - PASI value at Day 1) / Treatment difference on Day 43
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
Variables will be summarized by descriptive statistics (n, mean, SD), difference between groups is analyzed via non-parametric statistical testing.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="3.3994"/>
                    <measurement group_id="O2" value="-2.56" spread="5.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8785</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.09</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area Severity Index (PASI) - PASI Percentage Change - Including Subgroup Analysis AUC2h</title>
        <description>The PASI percentage change in % at Day 29 is calculated as PASI of (Day 29 - Baseline)/Baseline*100).
The PASI percentage change in % at Day 43 is calculated as PASI of (Day 43 - Baseline)/Baseline*100).
Baseline = Study Day 1
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD).</description>
        <time_frame>Study Day 1, 29 and 43</time_frame>
        <population>Patients of verum group were grouped into the following AUC subgroups according to AUC2h values estimated using the linear-logarithmic trapezoidal method on Day 1:
Group 1: 6 patients with the lowest AUCs; Group 2: 5 patients with the next highest AUCs; Group 3: 6 patients with the next highest AUCs; Group 4: 5 patients with the highest AUCs.</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032 PK Analysis Set</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Patients from the MP1032 group who provided plasma for PK purposes and completed the study.</description>
          </group>
          <group group_id="O2">
            <title>AUC_2h Subgroup 1</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Subgroup 1 according to AUC2h Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AUC_2h Subgroup 2</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Subgroup 2 according to AUC2h Day 1.</description>
          </group>
          <group group_id="O4">
            <title>AUC_2h Subgroup 3</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Subgroup 3 according to AUC2h Day 1.</description>
          </group>
          <group group_id="O5">
            <title>AUC_2h Subgroup 4</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Subgroup 4 according to AUC2h Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo PK Analysis Set</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient
Patients from the placebo group who provided plasma for PK purposes and completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area Severity Index (PASI) - PASI Percentage Change - Including Subgroup Analysis AUC2h</title>
          <description>The PASI percentage change in % at Day 29 is calculated as PASI of (Day 29 - Baseline)/Baseline*100).
The PASI percentage change in % at Day 43 is calculated as PASI of (Day 43 - Baseline)/Baseline*100).
Baseline = Study Day 1
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD).</description>
          <population>Patients of verum group were grouped into the following AUC subgroups according to AUC2h values estimated using the linear-logarithmic trapezoidal method on Day 1:
Group 1: 6 patients with the lowest AUCs; Group 2: 5 patients with the next highest AUCs; Group 3: 6 patients with the next highest AUCs; Group 4: 5 patients with the highest AUCs.</population>
          <units>Percentage - Change from Baseline Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.24" spread="24.069"/>
                    <measurement group_id="O2" value="-6.61" spread="25.575"/>
                    <measurement group_id="O3" value="-14.74" spread="24.96"/>
                    <measurement group_id="O4" value="-35.46" spread="22.891"/>
                    <measurement group_id="O5" value="-15.03" spread="16.422"/>
                    <measurement group_id="O6" value="-14.57" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.83" spread="29.853"/>
                    <measurement group_id="O2" value="3.06" spread="23.42"/>
                    <measurement group_id="O3" value="-21.82" spread="38.572"/>
                    <measurement group_id="O4" value="-38.31" spread="28.353"/>
                    <measurement group_id="O5" value="-14.32" spread="13.466"/>
                    <measurement group_id="O6" value="-15.56" spread="27.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area Severity Index (PASI) - PASI Percentage Change - Including Subgroup Analysis AUCt</title>
        <description>The PASI percentage change in % at Day 29 is calculated as PASI of (Day 29 - Baseline)/Baseline*100).
The PASI percentage change in % at Day 43 is calculated as PASI of (Day 43 - Baseline)/Baseline*100).
Baseline = Study Day 1
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD).</description>
        <time_frame>Study Day 1, 29 and 43</time_frame>
        <population>Patients of verum group were grouped into the following AUC subgroups according to AUCt values estimated using the linear-logarithmic trapezoidal method on Day 1:
Group 1: 6 patients with the lowest AUCs; Group 2: 5 patients with the next highest AUCs; Group 3: 6 patients with the next highest AUCs; Group 4: 5 patients with the highest AUCs.</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032 PK Analysis Set</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Patients from the MP1032 group who provided plasma for PK purposes and completed the study.</description>
          </group>
          <group group_id="O2">
            <title>AUC_t Subgroup 1</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Subgroup 1 according to AUCt Day 1.</description>
          </group>
          <group group_id="O3">
            <title>AUC_t Subgroup 2</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Subgroup 2 according to AUCt Day 1.</description>
          </group>
          <group group_id="O4">
            <title>AUC_t Subgroup 3</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Subgroup 3 according to AUCt Day 1.</description>
          </group>
          <group group_id="O5">
            <title>AUC_t Subgroup 4</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient
Subgroup 4 according to AUCt Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo PK Analysis Set</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient
Patients from the placebo group who provided plasma for PK purposes and completed the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area Severity Index (PASI) - PASI Percentage Change - Including Subgroup Analysis AUCt</title>
          <description>The PASI percentage change in % at Day 29 is calculated as PASI of (Day 29 - Baseline)/Baseline*100).
The PASI percentage change in % at Day 43 is calculated as PASI of (Day 43 - Baseline)/Baseline*100).
Baseline = Study Day 1
PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
No formal hypothesis testing, variables are summarized by descriptive statistics (n, mean, SD).</description>
          <population>Patients of verum group were grouped into the following AUC subgroups according to AUCt values estimated using the linear-logarithmic trapezoidal method on Day 1:
Group 1: 6 patients with the lowest AUCs; Group 2: 5 patients with the next highest AUCs; Group 3: 6 patients with the next highest AUCs; Group 4: 5 patients with the highest AUCs.</population>
          <units>Percentage - Change from Baseline Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.24" spread="24.069"/>
                    <measurement group_id="O2" value="-6.61" spread="25.575"/>
                    <measurement group_id="O3" value="-27.07" spread="33.055"/>
                    <measurement group_id="O4" value="-25.18" spread="19.510"/>
                    <measurement group_id="O5" value="-15.03" spread="16.422"/>
                    <measurement group_id="O6" value="-14.57" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.83" spread="29.853"/>
                    <measurement group_id="O2" value="3.06" spread="23.42"/>
                    <measurement group_id="O3" value="-35.88" spread="42.928"/>
                    <measurement group_id="O4" value="-26.59" spread="24.922"/>
                    <measurement group_id="O5" value="-14.32" spread="13.466"/>
                    <measurement group_id="O6" value="-15.56" spread="27.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area Severity Index (PASI) - PASI 30 and PASI 50 - Number of Patients</title>
        <description>PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
PASI 30 and PASI 50 are related to the number of patients who had at least 30% (PASI 30) or 50% (PASI 50) reduction in PASI score compared to baseline (Study Day 1).
Variables are summarized by descriptive statistics (n, mean, SD, ). Difference between groups has been analyzed via Fisher exact test.</description>
        <time_frame>Study Day 1, 29 and 43</time_frame>
        <population>Number of patients may vary between days due to drop outs or missing data points</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area Severity Index (PASI) - PASI 30 and PASI 50 - Number of Patients</title>
          <description>PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
PASI 30 and PASI 50 are related to the number of patients who had at least 30% (PASI 30) or 50% (PASI 50) reduction in PASI score compared to baseline (Study Day 1).
Variables are summarized by descriptive statistics (n, mean, SD, ). Difference between groups has been analyzed via Fisher exact test.</description>
          <population>Number of patients may vary between days due to drop outs or missing data points</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 30 - Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 - Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 30 - Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 - Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PASI 30 - Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PASI 50 - Day 29</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PASI 30 - Day 43</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5136</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PASI 50 - Day 43</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Area Severity Index (PASI) - PASI 30 and PASI 50 - Responder Frequency</title>
        <description>PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
PASI 30 and PASI 50 are related to the number of patients (responder frequency (%)) who had at least 30% (PASI 30) or 50% (PASI 50) reduction in PASI score compared to baseline (Study Day 1).
Variables are summarized by descriptive statistics (n, mean, SD, ).</description>
        <time_frame>Study Day 1, 29 and 43</time_frame>
        <population>Number of patients may vary between days due to drop outs or missing data points</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Area Severity Index (PASI) - PASI 30 and PASI 50 - Responder Frequency</title>
          <description>PASI is a total score computed over 4 body regions with 4 assessments ranging from 0 (no symptoms) to 4 (very marked). The total score ranges from 0 to 72.
PASI 30 and PASI 50 are related to the number of patients (responder frequency (%)) who had at least 30% (PASI 30) or 50% (PASI 50) reduction in PASI score compared to baseline (Study Day 1).
Variables are summarized by descriptive statistics (n, mean, SD, ).</description>
          <population>Number of patients may vary between days due to drop outs or missing data points</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 30 - Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.27"/>
                    <measurement group_id="O2" value="26.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 - Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09"/>
                    <measurement group_id="O2" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 30 - Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.78"/>
                    <measurement group_id="O2" value="21.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 50 - Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.04"/>
                    <measurement group_id="O2" value="17.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Assessment (PGA) - Observed Values and Change From Baseline</title>
        <description>PGA is the physician's global assessment of the severity of psoriasis using a 7-point scale from 0 (clear) to 6 (severe).
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at Study Day 43 (End of Treatment).</description>
        <time_frame>Study Day 1 and 43</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Assessment (PGA) - Observed Values and Change From Baseline</title>
          <description>PGA is the physician's global assessment of the severity of psoriasis using a 7-point scale from 0 (clear) to 6 (severe).
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at Study Day 43 (End of Treatment).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="0.8"/>
                    <measurement group_id="O2" value="4.4" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (End of Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.32"/>
                    <measurement group_id="O2" value="4.0" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.98"/>
                    <measurement group_id="O2" value="-0.4" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI) - Observed Values and Change From Baseline.</title>
        <description>DLQI is a total score ranging from 0 (life quality is not affected) to 30 (deep impact on life quality) computed from answers to 10 questions, with each answer scored from 0 (not at all) to 3 (very much).
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) on end of treatment (Day 43).</description>
        <time_frame>Study Day 1 and 43</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI) - Observed Values and Change From Baseline.</title>
          <description>DLQI is a total score ranging from 0 (life quality is not affected) to 30 (deep impact on life quality) computed from answers to 10 questions, with each answer scored from 0 (not at all) to 3 (very much).
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) on end of treatment (Day 43).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="3.68"/>
                    <measurement group_id="O2" value="8.6" spread="5.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (End of Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="4.66"/>
                    <measurement group_id="O2" value="7.3" spread="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="3.91"/>
                    <measurement group_id="O2" value="-1.3" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EQ-5D 5L Visual Analogue Scale (VAS)</title>
        <description>EQ-5D (VAS) is a total score which records the patients' self-rated health status with the scale numbered 0 (worst imaginable) to 100 (best imaginable)
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at end of Treatment (Study Day 43).</description>
        <time_frame>Study Day 1 and 43</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>EQ-5D 5L Visual Analogue Scale (VAS)</title>
          <description>EQ-5D (VAS) is a total score which records the patients' self-rated health status with the scale numbered 0 (worst imaginable) to 100 (best imaginable)
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at end of Treatment (Study Day 43).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="16.58"/>
                    <measurement group_id="O2" value="76" spread="11.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (End of Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="14.62"/>
                    <measurement group_id="O2" value="76.2" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="8.14"/>
                    <measurement group_id="O2" value="0.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Nail Psoriasis Severity Index (mNAPSI) - Observed Values and Change From Baseline</title>
        <description>mNAPSI score is a total score computed from answers to 7 questions, 3 of which can be answered with a score ranging from 0 to 3, and 4 of which can be answered with a score ranging from 0 to 1. The total score ranges from 0 to 13, the higher the score the worse the outcome.
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at end of Treatment (Study Day 43).</description>
        <time_frame>Study Day 1 and 43</time_frame>
        <population>Only patients with psoriatic nail disease were evaluated</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Nail Psoriasis Severity Index (mNAPSI) - Observed Values and Change From Baseline</title>
          <description>mNAPSI score is a total score computed from answers to 7 questions, 3 of which can be answered with a score ranging from 0 to 3, and 4 of which can be answered with a score ranging from 0 to 1. The total score ranges from 0 to 13, the higher the score the worse the outcome.
No formal hypothesis testing, variables will be summarized by descriptive statistics (n, mean, SD) for absolute values and changes from baseline (Study Day 1) at end of Treatment (Study Day 43).</description>
          <population>Only patients with psoriatic nail disease were evaluated</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.37"/>
                    <measurement group_id="O2" value="4.9" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43 (End of Treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.64"/>
                    <measurement group_id="O2" value="4.8" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.48"/>
                    <measurement group_id="O2" value="-0.1" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK) - Area Under the Curve (AUC)</title>
        <description>AUC (lin-log) - Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
AUC 2h = area under the plasma concentration-time curve from time zero to 2 hours AUC t = area under the plasma concentration-time curve from time zero to the last quantifiable concentration.</description>
        <time_frame>Study Day 1</time_frame>
        <population>PK analysis set - Per Protocol Set</population>
        <group_list>
          <group group_id="O1">
            <title>MP1032</title>
            <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) - Area Under the Curve (AUC)</title>
          <description>AUC (lin-log) - Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
AUC 2h = area under the plasma concentration-time curve from time zero to 2 hours AUC t = area under the plasma concentration-time curve from time zero to the last quantifiable concentration.</description>
          <population>PK analysis set - Per Protocol Set</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 2h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.161" spread="67.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC t</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.497" spread="63.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK) - Area Under the Curve (AUC) - Subgroups</title>
        <description>AUC (lin-log) - Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
AUC 2h = area under the plasma concentration-time curve from time zero to 2 hours AUC t = area under the plasma concentration-time curve from time zero to the last quantifiable concentration.</description>
        <time_frame>Study Day 1</time_frame>
        <population>PK analysis set - Per Protocol Set was divided into 4 Subgroups based on AUC levels for AUC 2h and AUC t, respectively. All patients received test product (100 mg MP1032 (= 2 capsules a 50 mg) provided orally twice daily for 42 days)</population>
        <group_list>
          <group group_id="O1">
            <title>AUC Subgroup 1</title>
            <description>6 patients with the lowest AUC 2h or AUC t, respectively</description>
          </group>
          <group group_id="O2">
            <title>AUC Subgroup 2</title>
            <description>5 patients with the next highest AUC 2h or AUC t, respectively</description>
          </group>
          <group group_id="O3">
            <title>AUC Subgroup 3</title>
            <description>6 patients with the next highest AUC 2h or AUC t, respectively</description>
          </group>
          <group group_id="O4">
            <title>AUC Subgroup 4</title>
            <description>5 patients with the highest AUC 2h or AUC t, respectively</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) - Area Under the Curve (AUC) - Subgroups</title>
          <description>AUC (lin-log) - Sampling 15 minutes, 30 minutes, 1 hour, and 2 hours postdose
AUC 2h = area under the plasma concentration-time curve from time zero to 2 hours AUC t = area under the plasma concentration-time curve from time zero to the last quantifiable concentration.</description>
          <population>PK analysis set - Per Protocol Set was divided into 4 Subgroups based on AUC levels for AUC 2h and AUC t, respectively. All patients received test product (100 mg MP1032 (= 2 capsules a 50 mg) provided orally twice daily for 42 days)</population>
          <units>h*ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subgroups AUC 2h</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.699" lower_limit="63.87" upper_limit="103.92"/>
                    <measurement group_id="O2" value="114.1" lower_limit="108.97" upper_limit="123.74"/>
                    <measurement group_id="O3" value="137.246" lower_limit="124.9" upper_limit="166.22"/>
                    <measurement group_id="O4" value="218.482" lower_limit="206.25" upper_limit="289.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subgroups AUC t</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.934" lower_limit="63.87" upper_limit="103.92"/>
                    <measurement group_id="O2" value="114.1" lower_limit="108.97" upper_limit="122.12"/>
                    <measurement group_id="O3" value="134.561" lower_limit="123.13" upper_limit="166.09"/>
                    <measurement group_id="O4" value="218.482" lower_limit="206.83" upper_limit="289.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data were collected from Enrolment to Last Visit (Study Day 71). All in all in each patient AEs were collected over a period of approximately 2-3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MP1032</title>
          <description>Test Product:
100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days
MP1032: hard gelatine capsules containing 50 mg MP1032 as active ingredient</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo:
2 capsules of Placebo are provided orally twice daily for 42 days
Placebo: hard gelatine capsules without active ingredient</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blood creatinine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus generalized</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Skin reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Officer</name_or_title>
      <organization>MetrioPharm Deutschland GmbH</organization>
      <phone>+49303384395 ext 36</phone>
      <email>info@metriopharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

